NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $17.11 -0.48 (-2.73%) Closing price 04:00 PM EasternExtended Trading$17.07 -0.04 (-0.23%) As of 04:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.05▼$17.7950-Day Range$16.50▼$27.8352-Week Range$15.85▼$30.96Volume1.90 million shsAverage Volume1.82 million shsMarket Capitalization$2.96 billionP/E Ratio8.11Dividend YieldN/APrice Target$31.13Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome. ACADIA also works to advance potential therapies for neurological and neurodevelopmental conditions. ACADIA’s commercial business is centered on the U.S. market. Catherine Owen Adams serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreACAD MarketRank™: 4.65562097768 of 5 starsACADIA Pharmaceuticals scored higher than 93% of companies evaluated by MarketBeat, and ranked 16th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on no strong buy ratings, 13 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialACADIA Pharmaceuticals has a consensus price target of $31.13, representing about 79.3% upside from its current price of $17.36.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth42.11% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 42.11% in the coming year, from $0.76 to $1.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 8.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.42.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 8.23, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.62.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.54% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.94.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 8.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for ACADIA Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest8 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $69,342.00 in company stock.Percentage Held by Insiders26.20% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACAD Stock News HeadlinesACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Target Cut by OppenheimerNovember 20 at 1:18 AM | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Biogen (BIIB), ACADIA Pharmaceuticals (ACAD) and Aveanna Healthcare Holdings (AVAH)November 19 at 6:00 PM | theglobeandmail.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 20 at 1:00 AM | Behind the Markets (Ad)Acadia Reports New Positive Data For Phase 2 Remlifanserin Study In Alzheimer's PsychosisNovember 18 at 10:03 AM | rttnews.comAcadia Alzheimer's psychosis drug remlifanserin missed main goal; CTAD meeting data due todayNovember 17 at 6:33 PM | msn.comAcadia Pharmaceuticals Inc. Presents Additional Phase 2 Radiant Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease PsychosisNovember 17 at 1:31 PM | marketscreener.comMTranscript : Acadia Pharmaceuticals Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 12:40 PMNovember 17 at 1:31 PM | marketscreener.comMInsider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 3,321 Shares of Company StockOctober 31, 2026 | insidertrades.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $26.71 on January 1st, 2026. Since then, ACAD stock has decreased by 35.0% and is now trading at $17.36. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its quarterly earnings data on Wednesday, November, 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.11. The company's quarterly revenue was up 22.8% on a year-over-year basis. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? Top institutional shareholders of ACADIA Pharmaceuticals include State Street Corp (4.43%), Goldman Sachs Group Inc. (2.67%), Allspring Global Investments Holdings LLC (0.89%) and Marshall Wace LLP (0.46%). Insiders that own company stock include Stephen Davis, Mark C Schneyer, Brendan Teehan, Austin D Kim, Elizabeth A Garofalo, James Kihara, Elizabeth HZ Thompson, Laura Brege, Jennifer J Rhodes and James M Daly. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Tesla (tsla), Alibaba Group (BABA) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings11/04/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ACAD's financial health is in the Red zone, according to TradeSmith. ACAD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia.com Phone(858) 558-2871Fax858-558-2872Employees798Year Founded1993Price Target and Rating Average Price Target for ACADIA Pharmaceuticals$31.13 High Price Target$38.00 Low Price Target$14.50 Potential Upside/Downside+81.9%Consensus RatingModerate Buy Rating Score (0-4)2.72 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$2.11 Trailing P/E Ratio8.11 Forward P/E Ratio15.84 P/E GrowthN/ANet Income$391 million Net Margins30.13% Pretax Margin13.08% Return on Equity8.90% Return on Assets6.86% Debt Debt-to-Equity RatioN/A Current Ratio3.82 Quick Ratio3.70 Sales & Book Value Annual Sales$1.20 billion Price / Sales2.46 Cash Flow$0.85 per share Price / Cash Flow20.10 Book Value$8.03 per share Price / Book2.13Miscellaneous Outstanding Shares172,829,000Free Float127,548,000Market Cap$2.96 billion OptionableOptionable Beta0.87 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ACAD) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredBlack Friday Special: Buy These Stocks Before Nov. 30thKeith Kaplan's firm has invested $17 million in its own AI research and tools, and 180,000 people worldwide no...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.